[go: up one dir, main page]

US20100004285A1 - POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID - Google Patents

POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID Download PDF

Info

Publication number
US20100004285A1
US20100004285A1 US12/561,148 US56114809A US2010004285A1 US 20100004285 A1 US20100004285 A1 US 20100004285A1 US 56114809 A US56114809 A US 56114809A US 2010004285 A1 US2010004285 A1 US 2010004285A1
Authority
US
United States
Prior art keywords
crystalline form
bilastine
liquid
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/561,148
Inventor
Aurelio Orjales Venero
Maravillas Bordell Martin
Gonzalo Canal Mori
Haydee Blanco Fuente
Maria Luisa Lucero De Pablo
Victor Rubio Royo
Ramon Mosquera Pestaña
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faes Farma SA
Original Assignee
Faes Farma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100004285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma SA filed Critical Faes Farma SA
Priority to US12/561,148 priority Critical patent/US20100004285A1/en
Publication of US20100004285A1 publication Critical patent/US20100004285A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention refers to a new crystalline form of 4-[2-[4-[1-(2-ethoxyethyl)-1H benzimidazole-2-yl]-1-piperidinyl]ethyl]- ⁇ -dimethyl-benzeneacetic acid (herein referred to as “bilastine”) of formula (I).
  • crystalline form 1 From hereon referred to as crystalline form 1, to procedures used to prepare it, to pharmaceutical formulae that contain crystalline form 1 and to the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals, such as man.
  • bilastine can exist in three different crystalline polymorphic forms, each with different physical properties.
  • the invention refers to crystalline form 1 of bilastine, characterised by X-ray crystallographic analysis, with approximate crystal parameters as follows:
  • the crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide tablet that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
  • FIG. 1 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 1. (Vertical axis: Transmission (%); Horizontal axis: Wavenumber (cm ⁇ 1 )).
  • FIG. 2 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 2. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm ⁇ 1 )).
  • FIG. 3 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 3. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm ⁇ 1 )).
  • bilastine can exist in three clearly different polymorphic forms called crystalline form 1, crystalline form 2 and crystalline form 3.
  • Crystalline form 3 is not very stable and is difficult to obtain in the pure form. Both crystalline form 2 and crystalline form 3 are converted into crystalline form 1 by the procedures of this invention.
  • Crystalline form 1 of bilastine has a melting point of 200.3° C.
  • Crystalline form 2 has a melting point of 205.2° C.
  • Crystalline form 3 has a melting point of 197.0° C.
  • the crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
  • the crystalline form 2 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • FIG. 2 represents the infrared spectrum of the crystalline form 2 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
  • the crystalline form 3 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • FIG. 3 represents the infrared spectrum of the crystalline 3 of the bilastine in a potassium bromide tablet recorded in Perkin Elmer Spectrum One FTIR spectrophotometer.
  • Crystalline form 1 of bilastine is a very stable polymorph at room temperature and is, therefore, very useful as an active ingredient of a pharmaceutical preparation. Crystalline form 1 is also stable when stored at temperatures above room temperature.
  • the crystalline form 1 of bilastine is characterised by the following data of its X-ray crystallographic analysis as a monocrystal, with crystal parameters of approximately the following values:
  • FIG. 1 shows the complete infrared spectrum of crystalline form 1 of bilastine in potassium bromide, recorded with Perkin Elmer Spectrum One spectrophotometer.
  • compositions of this invention can contain, as well as an effective quantity of crystalline form 1 of bilastine as an active ingredient as an antiallergic or antihistaminic agent, several pharmaceutically acceptable excipients.
  • the solid pharmaceutical preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • a solid excipient can be one of several substances that act as diluents, aromatising agents, agglutinants or disintegrating agents and an encapsulation material.
  • the powders and tablets preferentially contain from approximately 5 to approximately 20 per cent of the active ingredient.
  • Appropriate solid excipients are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, waxes with low melting point, cocoa butter and similar products.
  • preparation includes the formulation of the active ingredient with an excipient for encapsulation to produce a capsule in which the active ingredient (with or without other excipients) is surrounded with the excipient by an encapsulation material. Tablets, powders, cachets and capsules can be used as suitable forms for oral administration.
  • the active ingredient can also be incorporated into a chewing gum that can contain sweeteners, flavorings and colorings as appropriate.
  • a compound with a low melting point such as a mixture of fatty acid glycerides or cocoa butter
  • the active ingredient is mixed well and homogeneously dispersed in the mixture with agitation.
  • the homogeneous melted mixture is placed in the appropriate moulds and left to cool until it solidifies.
  • Liquid preparations comprise suspensions that can be made by mixing the finely divided active ingredient in water with suspension agents.
  • topical preparations are considered for nasal, ophthalmic and dermal use.
  • Appropriate formulae for nasal administration can correspond to solutions or suspensions.
  • Ophthalmic formulae can be suspensions and ointments.
  • Dermal preparations can be suspensions, ointments and creams.
  • Ointments usually contain lipophylic excipients such as mineral oil or vaseline.
  • a compound for transdermic use, consisting of a therapeutically effective amount of active ingredient incorporated into an excipient that corresponds to a liquid, a gel, a solid matrix or an adhesive patch sensitive to pressure, to be released via a transdermic administration system.
  • the effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for topical administration varies between 0.1 and 5% of the total weight of the pharmaceutical compound.
  • the preferred amount ranges from 0.1 to 2% of the total weight of the pharmaceutical compound.
  • the effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for oral administration varies from 1 to 50 mg/day, with preferably an amount corresponding to approximately 2 to 20 mg/day in a single or fractionated doses.
  • Crystalline form 1 of bilastine has antihistaminic properties that have been demonstrated in experimental pharmacological models, such as preventing histamine-induced lethality in the guinea-pig and antagonism against cutaneous capillary permeability induced by histamine in the rat.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-αα-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.
Figure US20100004285A1-20100107-C00001

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of application Ser. No. 10/511,822 having a filing date under 35 U.S.C. § 371(c) of Mar. 23, 2005, which is presently pending, and which, in turn, is a U.S. National Stage filing under 35 U.S.C. § 371 of International Patent Application No. PCT/ES02/00194 filed Apr. 19, 2002, the priority of which is claimed herein.
    • AREA OF THE INVENTION
  • The invention refers to a new crystalline form of 4-[2-[4-[1-(2-ethoxyethyl)-1H benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid (herein referred to as “bilastine”) of formula (I).
  • Figure US20100004285A1-20100107-C00002
  • From hereon referred to as crystalline form 1, to procedures used to prepare it, to pharmaceutical formulae that contain crystalline form 1 and to the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals, such as man.
    • BACKGROUND OF THE INVENTION
  • U.S. Pat. No. 5,877,187 confers the rights to bilastine, a preparation with antihistaminic properties without sedative or cardiovascular effects. This patent also concerns a procedure to prepare bilastine and the use of this preparation to treat allergic reactions in mammals but it does not include or suggest the possible existence of polymorphic forms of this compound. To prepare pharmaceutical preparations containing bilastine for their administration in mammals and especially in man, in accordance with international health authority specifications, bilastine must be manufactured in the most stable crystalline form possible, especially in a form that has constant physical properties.
    • SUMMARY OF THE INVENTION
  • We have found that bilastine can exist in three different crystalline polymorphic forms, each with different physical properties.
  • The invention refers to crystalline form 1 of bilastine, characterised by X-ray crystallographic analysis, with approximate crystal parameters as follows:
  •
    Crystallographic system Monoclinic
    Spatial group P2 (1)/c
    Crystal size 0.56 × 0.45 × 0.24 mm
    Cell dimension a = 23.38 (5) A angstrom α = 90°
    b = 8.829 (17) A β = 90°
    c = 12.59 (2) A γ = 90°
    Volume 2600 A3
    Z, calculated density 4, 1.184 mg/m3
  • The crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide tablet that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • 3430 (s)*; 3057 (w)*; 2970 (s); 2929 (s); 2883 (m)*; 2857 (m); 2797 (w); 1667 (m); 1614 (m); 1567 (w); 1509 (s); 1481 (m); 1459 (vs)*; 1431 (m); 1378 (w); 1346 (m); 1326 (m); 1288 (w); 1254 (m); 1199 (w); 1157 (w); 1121 (vs); 1045 (w); 1020 (w); 1010 (w); 991 (w); 973 (w); 945 (w); 829 (w); 742 (s); 723 (w); 630 (w), * where (w)=weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity. FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 1. (Vertical axis: Transmission (%); Horizontal axis: Wavenumber (cm−1)).
  • FIG. 2 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 2. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm−1)).
  • FIG. 3 shows a typical infrared absorption spectrum in potassium bromide of crystalline form 3. (Vertical axis: Transmission (%); Horizontal axis Wavenumber (cm−1)).
    •  DETAILED DESCRIPTION OF THE INVENTION
  • We have found that bilastine can exist in three clearly different polymorphic forms called crystalline form 1, crystalline form 2 and crystalline form 3.
  • The procedure described in U.S. Pat. No. 5,877,187 generates a mixture of crystalline forms 2 and 3. We have discovered experimental conditions and specific solvents to produce clearly different polymorphic forms of bilastin. The crystalline form 1 of pure bilastine is prepared according to the procedures of this invention. The crystalline forms 1 and 2 are stable.
  • Crystalline form 3 is not very stable and is difficult to obtain in the pure form. Both crystalline form 2 and crystalline form 3 are converted into crystalline form 1 by the procedures of this invention.
  • Crystalline form 1 of bilastine has a melting point of 200.3° C. Crystalline form 2 has a melting point of 205.2° C. Crystalline form 3 has a melting point of 197.0° C.
  • The crystalline form 1 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • 3430 (s)*; 3057 (w)*; 2970 (s); 2929 (s); 2883 (m)*; 2857 (m); 2797 (w); 1667 (m); 1614 (m); 1567 (w); 1509 (s); 1481 (m); 1459 (vs)*; 1431 (m);1378 (w); 1346 (m); 1326 (m); 1288 (w); 1254 (m); 1199 (w); 1157 (w); 1121 (vs); 1045 (w); 1020 (w); 1010 (w); 991 (w); 973 (w); 945 (w); 829 (w); 742 (s); 723 (w); 630 (w), * where (w)=weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity. FIG. 1 represents the infrared spectrum of the crystalline form 1 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer. The crystalline form 2 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • 3429 (s)*; 3053 (w)*; 2970 (s)*; 2932 (s); 2868 (s); 2804 (w); 1699 (m); 1614 (m)*; 1567 (m); 1508 (s); 1461 (vs)*; 1381 (m); 1351 (s); 1331 (m); 1255 (m); 1201 (w); 1156 (m); 1121 (vs); 1048 (w); 995 (w); 823 (w); 767 (w); 744 (s); 724 (w); 630 (w), * where (w) =weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity. FIG. 2 represents the infrared spectrum of the crystalline form 2 of the bilastine in a potassium bromide tablet recorded in a Perkin Elmer Spectrum One FTIR spectrophotometer.
  • The crystalline form 3 of bilastine is also characterised by its infrared absorption spectrum in potassium bromide that has the following characteristic absorption bands, expressed in reciprocal centimetres:
  • 3430 (s)*; 3053 (w)*; 2970 (s); 2932 (s); 2868 (s); 2804 (w); 1921 (w); 1708 (m)*; 1614 (m); 1568 (m); 1508 (s); 1461 (vs)*; 1380 (m); 1351 (m); 1330 (m); 1271 (m); 1255 (m); 1201 (w); 1156 (m); 1121 (vs); 1048 (w); 995 (w); 823 (m); 767 (w); 744 (s); 724 (w); 630 (w), * where (w) =weak intensity, (m)=medium intensity, (s)=strong intensity, (vs)=very strong intensity. FIG. 3 represents the infrared spectrum of the crystalline 3 of the bilastine in a potassium bromide tablet recorded in Perkin Elmer Spectrum One FTIR spectrophotometer.
  • We have discovered that, under selected experimental conditions, the mixture of the crystalline forms 2 and 3, obtained according to U.S. Pat. No. 5,877,187, is surprisingly transformed into crystalline form 1. We have also discovered that crystalline form 1 of bilastine is very stable and is not transformed into any of the other polymorphs 2 and 3. Similarly, in the same experimental conditions, the pure crystalline form 2 of bilastine is surprisingly transformed into the pure crystalline form 1. Crystalline form 3, which is the most unstable, undergoes the same transformation under the same conditions.
  • Crystalline form 1 of bilastine is a very stable polymorph at room temperature and is, therefore, very useful as an active ingredient of a pharmaceutical preparation. Crystalline form 1 is also stable when stored at temperatures above room temperature.
  • The crystalline form 1 of bilastine is characterised by the following data of its X-ray crystallographic analysis as a monocrystal, with crystal parameters of approximately the following values:
  •
    Crystallograph system Monoclinic
    Spatial group P2 (1)/c
    Crystal size 0.56 × 0.45 × 0.24 mm
    Cell dimension a = 23.38 (5) A angstrom α = 90°
    b = 8.829 (17) A β = 90°
    c = 12.59 (2) A γ = 90°
    Volume 2600 A3
    Z, calculated density 4, 1.184 mg/m3
  • During the development of crystalline form 1 of bilastine for pharmaceutical preparations, elaborated according to correct manufacturing procedures, we have discovered that crystallization of bilastine (prepared according to the description given in U.S. Pat. No. 5,877,187) from isopropylic alcohol and n-butanol, leads to generation of the polymorphic form 1 of bilastine with a high yield. Crystallisation from acetone, dimethylsulfoxide, dimethylformamide, acetonitrile and tetrahydrofurane or its mixtures thereof also lead to generation of crystalline form 1, although with lower yields. It is, therefore, preferable to use the former solvents.
  • The infrared spectrum of crystalline form 1 of bilastine in potassium bromide is characterised by the following bands, absent from polymorphs 2 and 3:
  • Wavenumber (cm−1)
    • 3057
    • 2929
    • 2883
    • 2857
    • 2797
    • 1667
    • 1481
    • 1431
    • 1346
    • 1326
    • 1288
    • 973
    • 945
    • 829
  • FIG. 1 shows the complete infrared spectrum of crystalline form 1 of bilastine in potassium bromide, recorded with Perkin Elmer Spectrum One spectrophotometer.
  • Pharmaceutical Preparations
  • Pharmaceutical preparations of this invention can contain, as well as an effective quantity of crystalline form 1 of bilastine as an active ingredient as an antiallergic or antihistaminic agent, several pharmaceutically acceptable excipients. The solid pharmaceutical preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. A solid excipient can be one of several substances that act as diluents, aromatising agents, agglutinants or disintegrating agents and an encapsulation material. The powders and tablets preferentially contain from approximately 5 to approximately 20 per cent of the active ingredient. Appropriate solid excipients are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, waxes with low melting point, cocoa butter and similar products. The term “preparations” includes the formulation of the active ingredient with an excipient for encapsulation to produce a capsule in which the active ingredient (with or without other excipients) is surrounded with the excipient by an encapsulation material. Tablets, powders, cachets and capsules can be used as suitable forms for oral administration. The active ingredient can also be incorporated into a chewing gum that can contain sweeteners, flavorings and colorings as appropriate.
  • To prepare suppositories, a compound with a low melting point, such as a mixture of fatty acid glycerides or cocoa butter, is melted and the active ingredient is mixed well and homogeneously dispersed in the mixture with agitation. The homogeneous melted mixture is placed in the appropriate moulds and left to cool until it solidifies.
  • Liquid preparations comprise suspensions that can be made by mixing the finely divided active ingredient in water with suspension agents.
  • Also, topical preparations are considered for nasal, ophthalmic and dermal use. Appropriate formulae for nasal administration can correspond to solutions or suspensions. Ophthalmic formulae can be suspensions and ointments. Dermal preparations can be suspensions, ointments and creams. Ointments usually contain lipophylic excipients such as mineral oil or vaseline.
  • Similarly, a compound is being contemplated for transdermic use, consisting of a therapeutically effective amount of active ingredient incorporated into an excipient that corresponds to a liquid, a gel, a solid matrix or an adhesive patch sensitive to pressure, to be released via a transdermic administration system.
  • The effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for topical administration varies between 0.1 and 5% of the total weight of the pharmaceutical compound. The preferred amount ranges from 0.1 to 2% of the total weight of the pharmaceutical compound.
  • The effective antiallergic or antihistaminic amount of crystalline form 1 of bilastine for oral administration varies from 1 to 50 mg/day, with preferably an amount corresponding to approximately 2 to 20 mg/day in a single or fractionated doses.
  • Crystalline form 1 of bilastine has antihistaminic properties that have been demonstrated in experimental pharmacological models, such as preventing histamine-induced lethality in the guinea-pig and antagonism against cutaneous capillary permeability induced by histamine in the rat.
  • The following examples illustrate but do not limit the scope of the present invention.
    • EXAMPLE 1
  • Preparation of crystalline form 1 of bilastine. Dissolve bilastine (see the U.S. Pat. No. 5,877,187) in isopropylic alcohol heated to reflux for approximately 15-20 minutes under nitrogen while stirring. Cool the solution to 50° C. over 6 hours and stop stirring. Let the solution cool to room temperature and stir again for three hours, filter and wash with cold isopropylic alcohol. Dry the solid residue in a vacuum oven at 35-40° C. to constant weight.
    • EXAMPLE 2
  • Preparation of crystalline form 1 of bilastine.
  • Heat a suspension of bilastine (see U.S. Pat. No. 5,877,187) in n-butanol and reflux for 3 hours under nitrogen while stirring. Leave the solution to cool while stirring, filter off the solid residue and dry it in a vacuum oven at 35-40° C. to constant weight.
    • EXAMPLE 3
  • Preparation of crystalline form 1 of bilastine.
  • Treat a mixture of polymorphs 2 and 3 of bilastine for several hours with hot acetone. Let the mixture cool to room temperature and filter off the solid residue. Dry it to constant weight.
    • EXAMPLE 4
  • Preparation of crystalline form 1 of bilastine.
  • Dissolve crystalline form 3 of bilastine in isopropylic alcohol heated to reflux and stir for approximately 15-20 minutes under nitrogen. Let the solution reach room temperature constantly stirring, filtering and washing with cold isopropanol. Dry the solid in a vacuum oven at 35-40° C. to constant weight.
    • EXAMPLE 5
  • Preparation of crystalline form 1 of bilastine.
  • Dissolve crystalline form 2 of bilastine in n-butanol heated to reflux while stirring for approximately 3 hours. Let the solution reach room temperature while stirring, filtering and draining. Dry the solid in a vacuum oven at 35-40° C. to constant weight.

Claims (8)

1. A liquid antihistaminic pharmaceutical composition comprising the crystalline form 1 of bilastine as the active ingredient together with at least one excipient, said crystalline form 1 of bilastine having, upon X-ray crystallography analysis, crystal parameters of substantially the following:
Crystallographic system Monoclinic Spatial group P2 (1)/c Crystal size 0.56 × 0.45 × 0.24 mm Cell dimension a = 23.38 (5) A angstrom α = 90° b = 8.829 (17) A β = 90° c = 12.59 (2) A γ = 90° Volume 2600 A3 Z, calculated density 4, 1.184 mg/m3,
an infrared spectrum in potassium bromide with the following bands:
Wavenumber (cm−1)
3057
2929
2883
2857
2797
1666
1481
1431
1346
1326
1288
1020
973
945
829
and an infrared spectrum in potassium bromide which is substantially identical to that shown in FIG. 1.
2. A liquid antihistaminic pharmaceutical composition according to claim 1, wherein said composition is a suspension.
3. A liquid antihistaminic pharmaceutical composition according to claim 1, wherein said composition is an emulsion.
4. A liquid antihistaminic pharmaceutical composition according to claim 1, wherein said composition is a lotion.
5. A liquid antihistaminic pharmaceutical composition according to claim 1, wherein said composition is a cream.
6. A liquid antihistaminic pharmaceutical composition according to claim 1, wherein said composition is an ointment.
7. A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient a liquid pharmaceutical composition according to claim 1.
8. A process for treating allergic diseases in a patient in need thereof, wherein the process comprises administering to said patient an effective amount of crystalline form 1 of bilastine in a liquid pharmaceutical composition according to claim 1.
US12/561,148 2002-04-19 2009-09-16 POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID Abandoned US20100004285A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/561,148 US20100004285A1 (en) 2002-04-19 2009-09-16 POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (en) 2002-04-19 2002-04-19 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic
US10/511,822 US7612095B2 (en) 2002-04-19 2002-04-19 Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid
ESPCT/ES02/00194 2002-04-19
US12/561,148 US20100004285A1 (en) 2002-04-19 2009-09-16 POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/511,822 Continuation US7612095B2 (en) 2002-04-19 2002-04-19 Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid

Publications (1)

Publication Number Publication Date
US20100004285A1 true US20100004285A1 (en) 2010-01-07

Family

ID=29225789

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/511,822 Expired - Lifetime US7612095B2 (en) 2002-04-19 2002-04-19 Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid
US12/561,148 Abandoned US20100004285A1 (en) 2002-04-19 2009-09-16 POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/511,822 Expired - Lifetime US7612095B2 (en) 2002-04-19 2002-04-19 Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid

Country Status (30)

Country Link
US (2) US7612095B2 (en)
EP (1) EP1505066B1 (en)
JP (1) JP5142448B2 (en)
KR (1) KR100673140B1 (en)
CN (1) CN1290843C (en)
AR (1) AR039423A1 (en)
AT (1) ATE347550T1 (en)
AU (1) AU2002255017B2 (en)
BG (1) BG66302B1 (en)
BR (1) BRPI0215703B8 (en)
CA (1) CA2484460C (en)
CY (2) CY1107564T1 (en)
CZ (1) CZ305162B6 (en)
DE (1) DE60216641T2 (en)
DK (1) DK1505066T3 (en)
ES (1) ES2278018T3 (en)
HR (1) HRP20041048B1 (en)
HU (1) HU230032B1 (en)
IL (1) IL164645A (en)
MX (1) MXPA04010313A (en)
NO (1) NO329327B1 (en)
NZ (1) NZ536551A (en)
PA (1) PA8571201A1 (en)
PE (1) PE20040086A1 (en)
PT (1) PT1505066E (en)
SI (1) SI1505066T1 (en)
SK (1) SK288052B6 (en)
UA (1) UA76866C2 (en)
UY (1) UY27762A1 (en)
WO (1) WO2003089425A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
WO2017191651A1 (en) * 2016-05-05 2017-11-09 Msn Laboratories Private Limited, R & D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (en) * 2009-09-09 2010-01-21 Faes Farma Sa POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
CN102675101B (en) * 2012-05-16 2014-01-29 王蕾 Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine
CZ307500B6 (en) 2012-08-15 2018-10-24 Zentiva, K.S. A method of the preparation of a 2-methyl-2'-phenylpropionic acid derivative employing novel intermediates
CN103214454A (en) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 Bilastine crystal and preparation method thereof
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (en) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 Bilastine-containing pharmaceutical composition and preparation method thereof
CN104447682A (en) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 Bilastine compound
CN104398481A (en) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 Bilastine orally disintegrating tablet and preparing method thereof
LT3327012T (en) 2015-07-24 2021-09-10 Urquima, S.A. CRYSTALLINE FORMS OF BILASTINE AND THEIR MANUFACTURING METHODS
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
ES2813561T3 (en) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Pharmaceutical composition in tablet comprising bilastine
EP3470062B1 (en) 2017-12-18 2020-10-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
WO2019097091A1 (en) 2017-12-18 2019-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler
US20210128544A1 (en) 2018-01-18 2021-05-06 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
EP4267109A1 (en) 2020-12-23 2023-11-01 Noucor Health S.A. A non-micronized bilastine composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877187A (en) * 1996-06-04 1999-03-02 Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) Benzimidazole derivatives with antihistaminic activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
MXPA01010472A (en) * 1999-04-16 2002-05-06 Reddy Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them.
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877187A (en) * 1996-06-04 1999-03-02 Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. (Faes) Benzimidazole derivatives with antihistaminic activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
WO2017191651A1 (en) * 2016-05-05 2017-11-09 Msn Laboratories Private Limited, R & D Center Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof

Also Published As

Publication number Publication date
CY2013015I2 (en) 2015-08-05
EP1505066B1 (en) 2006-12-06
CY2013015I1 (en) 2015-08-05
PA8571201A1 (en) 2003-12-10
IL164645A0 (en) 2005-12-18
ES2278018T3 (en) 2007-08-01
WO2003089425A1 (en) 2003-10-30
BRPI0215703B1 (en) 2017-06-27
JP5142448B2 (en) 2013-02-13
DK1505066T3 (en) 2007-03-19
CZ305162B6 (en) 2015-05-27
CN1628112A (en) 2005-06-15
NO20044999L (en) 2005-01-14
NZ536551A (en) 2006-08-31
EP1505066A1 (en) 2005-02-09
SI1505066T1 (en) 2007-04-30
PE20040086A1 (en) 2004-04-27
AU2002255017A1 (en) 2003-11-03
DE60216641D1 (en) 2007-01-18
CY1107564T1 (en) 2013-03-13
DE60216641T2 (en) 2007-09-27
KR20050005448A (en) 2005-01-13
CZ20041122A3 (en) 2005-03-16
IL164645A (en) 2010-11-30
MXPA04010313A (en) 2005-06-08
HRP20041048A9 (en) 2013-01-31
HRP20041048B1 (en) 2013-04-30
SK50202004A3 (en) 2005-05-05
HUP0500241A2 (en) 2005-06-28
CA2484460C (en) 2009-09-29
US20050203141A1 (en) 2005-09-15
HU230032B1 (en) 2015-05-28
HK1072772A1 (en) 2005-09-09
ATE347550T1 (en) 2006-12-15
NO329327B1 (en) 2010-09-27
PT1505066E (en) 2007-03-30
BG66302B1 (en) 2013-03-29
CN1290843C (en) 2006-12-20
BR0215703A (en) 2005-02-01
AU2002255017B2 (en) 2008-11-13
CA2484460A1 (en) 2003-10-30
UY27762A1 (en) 2003-09-30
KR100673140B1 (en) 2007-01-22
AR039423A1 (en) 2005-02-16
JP2005529120A (en) 2005-09-29
BG108941A (en) 2005-12-30
SK288052B6 (en) 2013-03-01
HRP20041048A2 (en) 2005-02-28
US7612095B2 (en) 2009-11-03
BRPI0215703B8 (en) 2021-05-25
UA76866C2 (en) 2006-09-15

Similar Documents

Publication Publication Date Title
US20100004285A1 (en) POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOLE-2-YL]-1-PIPERIDINYL]ETHYL]-alpha alpha-DIMETHYL-BENZENEACETIC ACID
EP1021439B1 (en) Crystalline antifungal polymorph
SK286422B6 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate, method for its production, pharmaceutical preparation containing thereof and its use
US6958337B2 (en) Crystalline antifungal polymorph
SK286197B6 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino) ethoxy]benzyl]- thiazolidine-2,4-dione maleic acid salt
KR100419404B1 (en) Vitreous form of known bradykinin antagonist
HK1072772B (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
RU2288917C2 (en) POLYMORPH OF 4-[2-[4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-PIPERIDINYL]ETHYL]-α,α-DIMETHYLBENZENEACETIC ACID, METHOD FOR ITS PREPARING, PHARMACEUTICAL PREPARATION BASED ON THEREOF AND ITS USING
US5106859A (en) Certain 1,3,4-thiadiazole derivatives and anti-ulcer agent comprising said derivatives as active ingredient
JP2010013472A (en) POLYMORPH OF 4-[2-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL] ETHYL-alpha,alpha-DIMETHYL BENZENOACETIC ACID
PL205568B1 (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g(a), $g(a)-dimethyl-benzeneacetic
HK1029588B (en) Crystalline antifungal polymorph

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION